Nature - 2019.08.29

2

nature research | reporting summary

October 2018

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size No statistical methods were used to predetermine sample sizes. Sample sizes were chosen in order to be able to perform statistical analyses,

as is standard in the field

Data exclusions No data were excluded from the analyses.

Replication To verify the reproducibility of our findings, experiments were performed using at least three biological replicates, unless clearly stated

otherwise in the figure legends. All attempts at replication were successful.

Randomization For in vivo mice experiments, mice were randomized into groups of equal average volumes.

Blinding For experiments involving human research participants, investigators were blinded to group allocation during data collection. For in vivo mice

experiments, investigators were not blinded to group allocation during data collection. For experiments involving cell culture, blinding did not

apply.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,

system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a Involved in the study

Antibodies

Eukaryotic cell lines

Palaeontology

Animals and other organisms

Human research participants

Clinical data

Methods

n/a Involved in the study

ChIP-seq

Flow cytometry

MRI-based neuroimaging

Antibodies

Antibodies used The following antibodies were used (all commercially available):

From Cell Signaling Technology (Danvers, MA, USA):

1. N-Myc (#9405, lot 2, 1:1,000);


2. N-Myc (#51705, Clone D4B2Y, lot 1);


3. Cleaved PARP Asp214 (#9541, lot 15, 1:4,000);


4. Cleaved caspase 3 Asp175 (#9661, lot 45, 1:500);


5. ALK (#3333, Clone C26G7, lot 7, 1:1,000);


6. Akt (pan) (#4691, Clone C67E7, lot 20, 1:4,000);


7. Phospho-Akt Thr308 (#9275, lot 26, 1:1,000);


8. Phospho-Akt Ser473 (#9271, lot 14, 1:2,000);


9. p44/42 MAPK (ERK1/2) (#4695, Clone 137F5, lot 21, 1:4,000);


10. Phospho- p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (#4377, Clone 197G2, lot 10, 1:4,000);


11. S6 Ribosomal Protein (#2217, Clone 5G10, lot 5, 1:8,000);


12. Phospho-S6 Ribosomal Protein (Ser235/236) (#4857, Clone 91B2, lot 2, 1:8,000);


13. Stat3 (#4904, Clone 79D7, lot 7, 1:2,000);


14. Phospho-Stat3 (Tyr705) (#9131, lot 30, 1:1,000);


15. MDR1/ABCB1 (#12683, Clone D3H1Q, lot 2, 1:5,000);


16. Sox2 (#3579, Clone D6D9, lot 8, 1:2,000);


17. β-Actin (#4967, multiple lots, 1:5,000);


18. CTCF (#3417, Clone D1A7, lot 1);


19. Normal Rabbit IgG (#2729, lot 7)